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Abstract 
Objective: The aim of this systematic review was to assess evidence on dental adverse effects associated 
with chemotherapy (CH) administered to children with cancer. 
Material and methods: Eight databases were searched without restrictions up to March 2017 for studies 
reporting on dental effects of CH administered for childhood cancer. After elimination of duplicates, data 
extraction, and risk of bias assessment according to the Cochrane guidelines, random-effects meta-
analyses of Relative Risks (RR) and Mean Differences (MD) and their 95% Confidence Intervals (CI) were 
performed, followed by meta-regression and sensitivity analyses. 
Results: The literature search identified a total of 15 non-randomized case-control studies including at least 
2315 patients (mean age at diagnosis or CH of 6.6 years; 36% male) followed for up to 22.9 years after 
CH. Meta-analysis indicated that CH was associated with increased risk for tooth agenesis compared to 
healthy controls (RR=2.47; 95% CI=1.30 to 4.71; P=0.006). This translated to every seventh child with CH 
having agenesis of at least one tooth that would not otherwise have. Additionally, CH was significantly 
associated with increased risk of tooth discoloration, arrested tooth development, enamel hypoplasia, 
microdontia, premature apexification, and decreased salivary flow rate, as well as worse oral hygiene and 
greater caries experience compared to controls. However, the strength of evidence was very low due to the 
inclusion of non-randomized study designs with high risk of bias. 
Conclusions: Current evidence from childhood cancer survivors indicates that chemotherapy is associated 
with considerable dental adverse effects that might be associated with greater burden of disease and 
treatment costs.  
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MAIN TEXT 
INTRODUCTION 
Rationale 
Considerable improvements have been seen during the last decades in the development of effective 
treatment protocols for childhood cancer, which usually consist of multiagent chemotherapy (CH), 
radiotherapy, or a combination of both. For example, the cure rate for Acute Lymphoblastic Leukemia (ALL), 
which is the most common childhood malignancy [1], has increased from less than 30% during the 1960s 
to an 80% to 86% 5-year overall survival [2]. 
Although developments in the curative therapy of childhood cancer have led to dramatic 
improvements in survival, mortality rates of childhood cancer survivors continue to be elevated for many 
years beyond 5-year survival compared to the general population [3]. Furthermore, childhood cancer 
survival is associated with many treatment-related late sequelae with potential effect on physical function 
including among others neurocognitive dysfunction, cardiopulmonary toxicity, endocrinopathy, and 
secondary malignancy, the frequency and severity of which depends on sex, age at diagnosis, and 
cumulative dose-exposures of specific treatment modalities [4-6]. Childhood cancer survivors are also 
prone to psychological distress that is associated with academic underachievement, underemployment, 
and functional limitations, which may adversely affect health status [7,8]. 
Likewise, several studies have assessed the potential impact of childhood cancer and its treatment 
on oral health status. As such, high prevalence of oral manifestations has been reported among pediatric 
cancer patients receiving CH that included among others gingivitis [9,10], caries [9-13], mucositis 
[10,13,14], cheilitis [10], oral pain [14], periodontitis [10], recurrent herpes [10], altered salivary 
immunological conditions [12,13], xerostomia [13,14], and disturbances in the number or development of 
teeth [9,11,12]. These adverse effects might have considerable impact on the functional or psychological 
status of childhood cancer survivors and ultimately their quality of life, while they may be associated with 
considerable financial burden. Therefore, the adoption of measures for the prevention or treatment of oral 
health related complications of childhood cancer treatment might be appropriate. 
The current evidence base for any adverse effects of cancer treatment on the teeth of children is 
rather bleak. Only a single systematic review exists on this subject [15] that has several issues like being 
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outdated, involving questionable a priori design, limited search, inadequate assessment of the included 
studies risk of bias, and no quantitative synthesis. Additionally, assessed interventions included 
radiotherapy, CH, and hematopoietic cell transplant treatment, even though evidence for both independent 
and additive effects of each treatment was found [15]. This makes accurate estimations about the 
contribution of each therapeutical approach to the development of adverse effects difficult and therefore 
has limited value from a preventive or therapeutic side. 
 
Aim 
Current evidence on short- or long-term dental complications of CH administered to children with cancer is 
limited. Therefore, aim of the present systematic review was to assess in an evidence-based manner the 
existing data from clinical studies on humans and try to answer the question: What are the adverse effects 
on the dentition and surrounding tissues of CH administered to children with cancer? 
 
MATERIAL AND METHODS 
Protocol and registration 
The review’s protocol was made a priori following the PRISMA-P statement [16], registered in PROSPERO 
(CRD42017058660), and all post hoc changes were appropriately noted. This systematic review was 
conducted and reported according to Cochrane Handbook [17] and PRISMA statement [18], respectively. 
 
Eligibility criteria 
According to the Participants Intervention Comparison Outcome Study design schema (PICOS), we 
included both randomized and non-randomized clinical studies on human children up to 18 years of age, 
sex, or ethnicity with any kind of cancer being treated with CH. The primary outcome of this systematic 
review was tooth agenesis, while the secondary outcomes included developmental defects of teeth, clinical 
inflammatory or caries indices, and salivary outcomes. Excluded were non-clinical studies, case reports, 
animal studies, and all studies where CH is combined with radiotherapy. 
 
Information sources and literature search 
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Eight electronic databases (MEDLINE, Cochrane Database of Systematic Reviews, Cochrane Central 
Register of Controlled Trials, Cochrane Database of Abstracts of Reviews of Effects, Virtual Health Library, 
Scopus, Web of Science, and ClinicalTrials.gov) were systematically searched by one author (SNP) without 
any limitations from inception up to March, 2017 (Appendix 1). Additionally, five sources (Google Scholar, 
International Standard Registered Clinical/ soCial sTudy Number Registry, Directory of Open Access 
Journals, Digital Dissertations, and metaRegister of Controlled Trials) and the reference/citation lists of 
included trials were manually searched for any additional trials. No limitations concerning publication 
language, publication year, or publication status were applied. 
 
Study selection 
The eligibility of identified studies was checked sequentially from their title, abstract, and full-text against 
the eligibility criteria by one person (DMB) and were subsequently checked independently by a second one 
(SNP), with any conflicts being resolved by a third person (TE). 
 
Data collection and data items 
Study characteristics and numerical data were extracted from included studies independently by two 
authors (DMB, SNP) using predefined and piloted extraction forms including: (i) study characteristics 
(design, clinical setting, country), (ii) patient characteristics (number, sex, age), (iii) cancer type, (iv) CH 
type, (v) follow-up after CH, and (vi) outcomes assessed. Piloting of the forms was performed during the 
protocol stage until over 90% agreement was reached. Missing or unclear information was calculated, 
whenever possible. 
 
Risk of bias in individual trials 
The risk of bias of included randomized trials was to be assessed using Cochrane’s risk of bias tool [17]. 
The risk of bias of included non-randomized studies (NRS) was assessed using the Newcastle-Ottawa 
scale for case-control studies [19]. 
 
Outcomes and data synthesis 
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The primary and secondary outcomes of this review were either binary or continuous and were expressed 
as Relative Risks (RR) or Mean Differences (MD), respectively with their corresponding 95% Confidence 
Intervals (CI). Statistically significant results were translated to their Numbers Needed to Treat (NNT) to 
gauge their clinical relevance. 
As adverse effects of CH are bound to be affected by the patient’s age, dental/skeletal growth 
phase, cancer type, CH type or duration, and the patient’s immunologic response, a wide variation of true 
effects was expected and a random-effects model was judged a priori sensible, based on biological, clinical, 
and statistical grounds [20]. The alternative Paule-Mandel random-effects estimator was used instead of 
the more widely known DerSimonian and Laird [21] one, based on contemporary guidelines, due to its 
improved performance [22]. 
The extent and impact of between-study heterogeneity was assessed by inspecting the forest plots 
and calculating the tau2 and the I2, respectively; I2 defines the proportion of total variability in the result 
explained by heterogeneity, and not by chance [23]. Heterogeneity was roughly categorized as low 
moderate, and high according to I2 values of 25%, 50%, and 75% [23], although the heterogeneity’s 
localization on the forest plot was also examined. Additionally, the 95% CIs around tau2 and I2 were 
calculated [24] to quantify our uncertainty around these estimates. 95% predictive intervals were calculated 
for meta-analyses of ≥3 trials to incorporate existing heterogeneity and provide a range of possible effects 
for a future clinical setting [25]. All analyses were conducted in Stata SE version 14.2 (StataCorp LP, 
College Station, Texas, USA) by one author (SNP) and the dataset was made freely available [26]. A two 
side P≤0.05 was considered significant for hypothesis-testing, except for P≤0.10 used for tests of between-
studies or between-subgroups heterogeneity [27]. 
 
Additional analyses and quality of meta-evidence 
Possible sources of heterogeneity were a priori planned to be sought through mixed-effects subgroup 
analyses and random-effects meta-regression for meta-analyses of ≥ five studies according to (i) patient 
characteristics (age, sex, ethnicity, cancer type, phase of dentition, oral health) (ii) preventive or therapeutic 
interventions administered prior to or during CH, and (iii) CH-related characteristics, but could not be 
ultimately conducted. 
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Robustness of the results was planned a priori to be checked with sensitivity analyses based on (i) 
inclusion/exclusion of trials with methodological shortcomings, (ii) improvement of the GRADE 
classification, and (iii) inclusion/exclusion of large-scale studies (judged arbitrarily as having at least 100 
patients). 
The overall quality of meta-evidence (i.e. the strength of clinical recommendations) was rated using 
the Grades of Recommendations, Assessment, Development, and Evaluation (GRADE) approach, as very 
low, low, moderate, or high [28] and Summary of Findings tables were constructed using the improved 
format proposed by Carrasco-Labra et al. [29]. The minimal clinical important [30], large, and very large 
effects were defined as half, one, and two standard deviations (using the average standard deviation for an 
outcome across included studies), respectively. Arbitrary cut-offs of 1.5, 2.0, and 5.0 [31] were adopted for 
RR. The produced forest plots were augmented with contours denoting the magnitude of the observed 
effects [32] to assess heterogeneity, clinical relevance, and imprecision. 
 
RESULTS 
Study selection 
The literature search yielded a total of 741 hits (Fig. 1), 92 of which proceeded to full text assessment after 
eliminating duplicates and ineligible studies by title or abstract (Appendix 2). Finally, a total of 16 papers 
were identified as eligible for inclusion in the present systematic review. After pooling multiple papers 
relating to the same study, a total of 15 unique clinical studies published in English between 1987 and 2016 
were included. 
 
Study characteristics 
The descriptive characteristics of the 15 included studies can be seen in Table 1a and Table 1b [12,13,33-
46]. From these, none was a randomized clinical trial and all were retrospective non-randomized studies. 
Most studies were conducted in university clinics (n=12; 80%) in 12 different countries. Overall, at least 
2315 patients were included (from the 15 studies reporting patient sample) with a mean age of diagnosis 
or CH 6.6 years (from the 8 studies reporting this age) and with 36% of the patients being male (from the 
12 studies reporting even partly patient sex). These patients had been treated with various types of CH and 
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re-examined either during CH (3 studies) or after an average follow-up period ranging from 1.4 to 22.9 
years post CH (from the 9 studies reporting mean follow-up). The primary outcome of tooth agenesis was 
the most popular (assessed in the same way from 5 studies), followed by the secondary outcomes of 
microdontia, premature apexification, caries experience (through the Decayed-Missing-Filled-Teeth [DMFT] 
index), plaque/gingival indices, enamel hypoplasia, arrested root development, tooth discoloration, salivary 
buffer capacity or flow rate, and Streptococcus mutans counts. 
 
Risk of bias within studies 
The methodological adequacy (with possible effects on its bias risk) of identified studies with the Newcastle-
Ottawa tool is given in detail in Appendix 3 and summarized in Table 2. The selection of cases/controls was 
found to be good in 5 (33%) of the studies, very good in 7 (47%) of the studies, and perfect in 3 (20%) of 
the studies. The comparability of cases and controls was poor in 5 (33%) of the studies, partial in 3 (20%) 
of the studies, and perfect in 7 (47%) of the studies. Finally, the domain of exposure was limited in 10 (67%) 
of the studies, partially adequate in 4 (27%) of the studies, and adequate in one (7%) of the studies. This 
latter study [46] was the single study that completely fulfilled all three domains, while the remaining 14 
studies had at least one limitation in a domain. 
 
Results of individual studies and data synthesis 
The results of the primary and secondary outcomes from each included study can be found in the provided 
dataset [26], while the re-analysis of raw data provided in tabular form by a single study [35] is given in 
Appendix 4. As far as data synthesis of the primary outcome is concerned, CH was associated with a 
considerable increase in the risk of tooth agenesis compared to untreated patients (5 studies; RR=2.47; 
95% CI=1.30 to 4.71; P=0.006; Table 3; Fig. 2). Moderate to considerable heterogeneity was seen, but 
estimates were highly imprecise for both absolute heterogeneity (tau2=0.31; 95% CI=0 to 5.03) and relative 
heterogeneity (I2=61%; 0% to 96%), which resulted in a very wide random-effects prediction for prospective 
CH patients with RRs ranging from 0.32 to 19.40. The average effect of CH on tooth agenesis was 
translated to an NNT of 7, which means that every 7th child with cancer exposed to CH may develop tooth 
agenesis that he or she would not have otherwise (Table 4). 
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As far as the secondary outcomes are concerned, CH was associated with statistically significant 
(P<0.05) increases in the risk of microdontia (4 studies; RR=12.41; Fig. 3), enamel hypoplasia (2 studies; 
RR=3.08), arrested tooth development (2 studies; RR=2.75), premature apexification (3 studies; RR=4.53; 
Fig. 4), and tooth discoloration (2 studies; RR=3.25). Additionally, CH was associated with statistically 
significant (P<0.05) increases in the average plaque index (3 studies; MD=0.60 units), gingival index (3 
studies; MD=0.38 units), DMFT index (3 studies; MD=3.07 teeth), and DT index (2 studies; MD= 3.55 teeth), 
as well as with significant decreases in the MT index (2 studies; MD=-0.56 teeth) and salivary flow rate (2 
studies; MD= -0.19 ml/min). As far as the magnitude of observed effects is concerned (Table 4), the greatest 
increase in the risks of adverse effects was seen for tooth discoloration (where every 2nd child with CH 
would be affected), arrested root development (where every 4th child with CH would be affected), and 
enamel hypoplasia (where every 8th child with CH would be affected). 
 Finally, the GRADE approach was used to assess the quality of meta-evidence for the primary and 
secondary outcomes (Table 5a and 5b). As all analyses were based on non-randomized studies with high 
risk of bias due to methodological shortcomings, the confidence in the estimates is very low according to 
the GRADE approach for all outcomes. Large effect magnitudes were seen for some outcomes with 
NNTs<10 (Table 4), but no upgrade was done, due to existing methodological limitations. 
 
Additional analyses 
Several subgroup and sensitivity analyses were planned in the review’s protocol, but could not be eventually 
performed as only one meta-analysis included at least 5 studies and their reporting of patient or treatment 
details was suboptimal. Only meta-regressions of tooth agenesis with patient age, patient sex, and follow-
up duration could be conducted (Appendix 5), which did not find any significant modifying effect. 
Likewise, two planned sensitivity analyses could not be conducted, as no randomized and no 
prospective non-randomized studies were ultimately identified. A sensitivity analysis according to sample 
size of the included studies (Appendix 6) indicated that the results were robust enough. 
 
DISCUSSION 
Summary of evidence 
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To our knowledge this is the first study to summarize and assess in a systematic manner the adverse effects 
on the teeth or surrounding tissues of childhood cancer survivors after CH. The literature search yielded a 
total of 15 identified non-randomized studies including at least 2315 patients (mean age at diagnosis or CH 
of 6.6 years; 36% male) followed for up to 22.9 years post CH. 
Synthesis of available evidence indicated that CH was associated with increased risk for tooth 
agenesis by 147% (RR=2.47; Table 3). This translates clinically to every 7th child with CH having agenesis 
of at least one permanent tooth that would not develop otherwise (Table 4). This has been mostly attributed 
to intensive and repetitive CH at the time of initial hard-tissue formation [47]. 
Furthermore, CH was associated with additional developmental disturbances of the teeth including 
premature apexification, microdontia, enamel hypoplasia, arrested root development, and tooth 
discoloration – with the last three being most strongly associated with CH. Tooth discolorations and enamel 
hypoplasia could be attributed to CH agents like vincristine, vinblastine, and cyclophosphamide that might 
disturb ameloblast function, such as their microtubule calcium transport mechanism [42]. Microdontia or 
root malformations may be attributed to CH agents like vinblastine and vincristine that can interfere with the 
secretory function of mature odontoblasts / ameloblasts, which disrupts collagen fibril formation and dentin 
matrix secretion [12]. 
There are reports in the literature that dental developmental disturbances from CH are closely 
related to the patient’s chronological or dental age—with younger patients being more severely affected 
[48-50]. In the present review the effect of patient age on dental adverse effects of CH could not be 
appropriately assessed through subgroup analysis or meta-regression, due to the limited material. Two 
identified studies providing different age subgroups indicated that potential differences existed between 
patients up to 5 years old and patients 6 years or older for tooth agenesis (RRs of 2.14 versus 0.67, 
respectively; 1 study), for microdontia (RRs of 10.70 versus 0.62, respectively; 1 study), and premature 
apexification (RRs of 8.50 versus 1.88, respectively; 1 study). On the other hand, age did not seem to have 
a big influence on arrested root development (RRs of 2.99 and 2.17; 2 studies) or tooth discoloration (RRs 
of 2.72 or 3.32; 1 study). However, these explorative findings could not be formally confirmed with robust 
evidence in the present review and caution is warranted by their interpretation. 
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 The oral hygiene of CH patients was also significantly worse than controls, which was reflected in 
increased plaque accumulation and gingivitis (Table 3). However, this is not attributed directly to CH for 
example due to motoric disturbances of CH patients, but might be associated with specific phases of the 
antineoplastic treatment with low thrombocyte levels, where patients are instructed to refrain from 
toothbrushing to avoid bacteremia [51]. However, this suggested discontinuation of toothbrushing during 
thrombocytopenic and/or neutropenic phases is not shared by other researchers [52]. It is believed that 
thrombocytopenia should not be the sole determinant of oral hygiene procedures, as patients are able to 
perform oral hygiene procedures without bleeding at widely different levels of platelet counts [53]. However, 
in order to decrease the risk of any microtraumas due to toothbrushing, foam brushes and rinsing solutions 
can be recommended to perform oral hygiene during myeloablative chemotherapy instead of conventional 
toothbrushes [54]. In cases of preexisting mucosal irritation or thrombocytopenic hemorrhage, cotton swabs 
or sponges can be used instead of a toothbrush [55]. Other researchers suggest that throughout CH, the 
toothbrush should be placed in a 2% chlorhexidine solution which is replaced after each use in order to 
prevent bacterial contamination [56]. Another study indicated that the use of a fluoride gel led to significant 
improvement of the patients’ caries experience throughout CH and could be a viable solution [35]. As no 
widely-accepted protocol for dental hygiene during CH exists at the time, future research on the 
effectiveness and adverse effects of various hygiene schemes might be prudent.  
The average salivary flow rate among children treated with CH was significantly decreased 
compared to control patients (MD=-0.19 ml/min; Table 3). Hyposalivation has been reported in the literature 
as a direct consenquence of CH and has been observed even 5 years after CH [41]. 
Additionally, considerably greater caries experience was seen among CH patients than in controls 
in terms of higher DMFT index (MD=3.07 teeth; Table 3), which was attributed to significantly greater caries 
prevalence (DT; MD=3.55 teeth) and significantly less missing teeth (MT; MD=-0.56 teeth). The increased 
caries prevalence of CH patients might be explained by many factors. For one, CH-associated reduced 
salivary flow alters the microflora of the oral cavity, favoring caries-related bacteria [56]. Additionally, 
children on CH might require mouth moistening due to the existing hyposalivation / xerostomia, which is 
sometimes done by soft drinks that contain sugar [57]. However, other studies on children who received 
regular preventive protocols during CH found no differences in oral health parameters compared to controls 
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[58,59]. Generally, it is believed that the effect of CH on dental caries seems not to be a direct one, but 
rather an indirect consequence of poor oral hygiene and a lack of professional dental care during and after 
CH. 
Finally, it must be noted that CH patients have been reported to have an increased burden of oral 
lesions compared to healthy patients, which sometimes develop into ulcers [34]. However, this could not 
be formally included in meta-analysis, due to the limited number of contributing studies and the nature of 
the measurements. Some evidence indicates that toothbrushing CH patients might have different 
progression of oral lesions than non-toothbrushing CH patients [34], while for both groups the presence of 
caries at the outset increased the probability of oral lesions during chemotherapy. Finally, the use of a novel 
hospital oral care protocol including toothbrushing has been shown to lead to a reduction in the prevalence 
of mucositis among CH patients [60], indicating potential gains of introducing such a systematic approach 
to the oral health of the pediatric cancer patiens. 
 
Strengths and limitations 
The strengths of this systematic review consist of the registration of its a priori protocol in PROSPERO [61] 
with transparent reporting of all post hoc actions [Appendix 7], its exhaustive literature search, its improved 
analytical methods [22], the use of the GRADE approach [28] to assess the quality of the meta-evidence, 
and open provision of the study dataset [26]. However, certain limitations also exist. First and foremost, this 
systematic review included only non-randomized trials that are at higher risk of bias than randomized ones 
[62]. As the scope of the review pertained more to adverse effects and diagnosis, non-randomized designs 
might be applicable [63], but all included studies were retrospective and therefore at higher risk of bias than 
prospective non-randomized studies [64]. Additionally, methodological issues existed for all included 
studies and these might have influenced the review’s results. Finally, the limited number of included studies 
and their suboptimal reporting did not enable robust assessments of heterogeneity, as well as the conduct 
of several analyses for subgroup, small-study effects, and reporting biases that were planned a priori. 
 
Clinical recommendations 
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Existing evidence from observational case-control studies indicates that chemotherapeutic medications in 
the treatment of childhood cancer is associated with disturbances of tooth development (tooth agenesis, 
tooth discoloration, arrested tooth development, enamel hypoplasia, microdontia, premature apexification), 
worse oral hygiene, oral lesions, hyposalivation, and increased caries experience compared to healthy 
children. Due to these detrimental effects on oral health, it is imperative that efforts are put forwards towards 
minimizing these adverse effects, so that cancer survivors have a better quality of life [65]. For example, it 
might be prude to do dental consultations on newly diagnosed children so that any pending preventive or 
therapeutic dental treatment can be concluded before the start of the antineoplastic therapy [52]. Some 
suggest that childhood cancer survivors are considered as a high-risk dental group and therefore need a 
close cooperation between the pediatric dentist and the pediatric oncologist. Consequently, a flexible 
cancer management scheme that also includes funds for preventive dentistry as well as hospital care 
pertaining to dental care and diet counseling [50,55] might be appropriate. 
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FIGURES & LEGENDS 
Fig. 1. PRISMA flow diagram for the identification and selection of eligible studies. 
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Fig. 2. Contour enhanced forest plot with random-effects meta-analysis on the prevalence of tooth agenesis among chemotherapy children and 
untreated children. CH, chemotherapy group; CI, confidence interval; CTR, control (non-chemotherapy) group; RR, relative risk.  
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Fig. 3. Contour enhanced forest plot with random-effects meta-analysis on the prevalence of microdontia among chemotherapy children and 
untreated children. CH, chemotherapy group; CI, confidence interval; CTR, control (non-chemotherapy) group; RR, relative risk. 
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Fig. 4. Contour enhanced forest plot with random-effects meta-analysis on the prevalence of premature apexification among chemotherapy 
children and untreated children. CH, chemotherapy group; CI, confidence interval; CTR, control (non-chemotherapy) group; RR, relative 
risk. 
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Table 1a 
Characteristics of included studies. 
Study ID 
Design; setting; 
country* 
Patients (M/F) 
CH age† 
(yrs) 
Evaluation age 
(yrs) 
Follow-up 
(yrs) 
Cancer 
type 
CH type 
Dental 
care 
Alpaslan 1999 
[33] 
NRS; Uni; TR 
CH: 30 (23/7) 
NC: 20 (15/5) 
NR 
CH: 10.2 
NC: 10.3 
1.4 post 
CH 
HL, nHL 
COPP, ABVD / BFM-90, 
LSA2L2 
NR 
Avşar 2007 [12] NRS; Uni; TR 
CH: 96 (48/48) 
NC: 96 (48/48) 
6.4 
CH: 10.8 
NC: 10.5 
2.5 post 
CH 
Various NR No 
Bonnaure-Mallet 
1998 [34] 
NRS; Uni; FR CH: 131 (74/57) 6.6 NR During CH Various NR 
Prior/durin
g CH 
Cubukcu 2008$ 
[35] 
NRS; Uni/Reg; TR 
CH: 33 (21/12) 
NC: 34 (22/12) 
NR 
CH: 9.5 
NC: 9.4 
5.0 post 
CH 
Various Various 
(Some) 
during CH 
Dens 1995 [36] NRS; Uni; BE 
CH: 52 (NR) 
NC: 63 (NR) 
NR 
CH: (2.0-17.0) 
NC: similar 
4.1 post 
CH 
Various NR No 
El –Housseiny 
2007 [37] 
NRS; Uni; EG CH: 150 (82/68) NR CH: 7.0 NR Various Various NR 
Hutton 2010 [38] NRS; Uni/Reg; GB 
CH: 120 (69/51) 
NC: NR (matched) 
(0-15.0) CH/NC: (0-17.0) 
4.3 post 
CH 
Various 
Anthracycline, alkylating, or 
platinum drugs 
NR 
Krasuska-
Sawiska 2016 
[39] 
NRS; Hosp; PL 
CH: 120 (NR) 
NC: 60 (NR) 
7.5 
CH: 11.5 
NC: 12.2 
2.5 post 
CH 
Various Various 
Prior/durin
g/after CH 
Nemeth 2013 
[40]; 2014 [41] 
NRS; Uni/Sch; HU 
CH: 38 (22/16) 
NC: 40 (18/22) 
4.3 
CH: 12.2 
NC:12.5 
6.9 post-
CH 
NR Various No 
Oguz 2004 [42] NRS; Uni; TR 
CH: 36 (29/7) 
NC: 36 (matched) 
7.1 
CH: 10.0 
NC: matched 
2.6 post-
CH 
nHL BFM-90; LSA2L2; LMT-89 NR 
Ou-Yang 2010 
[43] 
NRS; Uni; TW 
CH: 46 (NR) 
NC: 46 (matched) 
7.5 
CH: 7.5 
NC: matched 
During CH ALL Various 
(Some) 
after CH 
Pedersen 2012 
[44] 
NRS; Reg; DK 
CH: 150 (NR) 
NC: 193 (NR) 
(1.0-7.0) 
CH/NC: (12.0-
18.0) 
NR Various Various NR 
Rosenberg 
1987§ [45] 
NRS; Hosp or Uni; 
US 
CH: 17 (NR) 7.2 CH: ≥14.0 NR ALL L-2, L-10, or off-protocol NR 
Thomaz 2013 
[13] 
NRS; Uni/Sch; BR 
CH: 20 (13/7) 
NC: 22 (NR) 
NR 
CH/NC: (3.0-
15.0) 
During CH ALL Ct (GBTLI-99), BFM-83 NR 
Wilberg 2016 
[46] 
NRS; Uni; NO 
CH: 111 (50/61) 
NC: 555 (263/292) 
6.2 
CH: 29.1 
NC: 29.1 
22.9 years 
post-CH 
ALL Norwegian / NSPHO protocol 
(Some) 
after CH 
* countries are given with their ISO Alpha-2 code. 
† age pertains to diagnosis or treatment start and is given as mean (or in absence of mean as range in parenthesis). 
$ some patients received also radiotherapy—those were excluded from the analyses. 
§ compares treated patients with a historical sample of 10 other studies. 
 
ABVD: Adriamycin, Bleomycin, Vinblastine, Dacarbazine protocol; ALL: Acute lymphoblastic leukemia; BFM: Berlin–Frankfurt–Münster-90 protocol; CH: chemotherapy (group); 
COPP: Cyclophosphamide, Oncovin, Procarbazine Hydrochloride, and Prednisone; HL: Hodgkin’s lymphoma; Hosp: hospital clinic; M/F: male/female; mos: months; NC: no 
chemotherapy group; nHL: non-Hodgkin’s lymphoma; NR: not reported; NRS: non-randomized study; NSPHO, Nordic Society of Pediatric Haematology and Oncology; Pat: 
patients; Reg: registry; Sch: school; Uni: university clinic; Hosp: Hospital; yrs: years.  
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Table 1b 
Outcomes assessed by included studies. 
Study ID Outcomes 
Alpaslan 1999 [33] 
Eruption status; root malformations; premature apexification; agenesis, crown anomalies; soft tissue abnormalities; GI; PI; enamel defects 
and discolorations; hypoplasia; dmft/s; DMFT/S; cephalometric measurements 
Avşar 2007 [12] 
DMFT; GI; PI; Salivary flow rate; salivary buffer capacity; SM and LB counts; enamel disturbances (white/cream opacity, yellow/brown 
opacity, fine white lines, hypoplasia); dental development disturbances 
Bonnaure-Mallet 1998 [34] Frequency, severity and progress of oral lesions; caries at baseline 
Cubukcu 2008 [35] dmft/DMFT 
Dens 1995 [36] sIgA/IgG; Caries prevalence (DMFT/dmft); PI; SM/Lb counts 
El –Housseiny 2007 [37] Mucositis; fungal/viral/bacterial infected lesions; PI; GI; dmft/DMFT 
Hutton 2010 [38] dmft/DMFT; enamel opacities; Microdontia; dental trauma; dental trauma; gingival health 
Krasuska-Sawiska 2016 
[39] 
PI; GI; dmft/DMFT; WSL; enamel defects (opacities, hypoplasia, combination); mucositis 
Nemeth 2013 [40]; 2014 
[41] 
DMFT; salivary flow rate; salivary buffer capacity; bleeding and calculus; OHI-S; debris index; calculus index; agenesis; microdontia; 
macrodontia; unerrupted teeth; root malformation 
Oguz 2004 [42] 
PI; GI; dmft/s, DMFT/S; dmfs/DMFS; enamel discoloration; enamel defect; root malformations; unerupted teeth; agenesis; premature 
apexification; microdontia 
Ou-Yang 2010 [43] DEFTS/DMFT; SM and LB counts; salivary buffer capacity 
Pedersen 2012 [44] Microdontia; hypodontia 
Rosenberg 1987 [45] Root development (shortening, blunting of the apex, tapering/narrowing) 
Thomaz 2013 [13] Oral lesions; caries experience; PI; GI; deft/DMFT; sIgA 
Wilberg 2016 [46] Xerostomia; microdontia; enamel hypoplasia; hypodontia; DMFT; BOP; IDel 
BOP: bleeding on probing; deft: decayed, extracted, and filled deciduous tooth; DEFTS: edecayed, extracted, and filled permanent tooth surface; DMFT: Decayed Missing 
Filled Teeth for adult dentition (dmft for deciduous dentition); GI: gingival index; IDeI: individual defect index; LB: Lactobacillus; OHI-S: simplified oral health index; PI: 
plaque index; sIgA: salivary immunoglobin A; sIgG: salivary immunoglobin G; SM: Streptococcus mutans; WSL: White spot lesion. 
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Table 2 
Methodological issues (with possible association to risk of bias) of included non-randomized studies with the Newcastle-Ottawa scale. 
Study Selection Comparability Exposure 
Total 
stars 
Alpaslan 1999 [33] ۞۞۞ ۞۞ ۞ 6/9 
Avşar 2007 [12] ۞۞۞ ۞۞ ۞ 6/9 
Bonnaure-Mallet 1998 [34] ۞۞   ۞ 3/9 
Cubukcu 2008 [35] ۞۞۞۞ ۞۞ ۞ 7/9 
Dens 1995 [36] ۞۞ ۞ ۞ 4/9 
El –Housseiny 2007 [37] ۞۞   ۞ 3/9 
Hutton 2010 [38] ۞۞۞ ۞ ۞ 5/9 
Krasuska-Sawiska 2016 
[39] 
۞۞ ۞ ۞ 4/9 
Nemeth 2013 [40]; 2014 
[41] 
۞۞۞ ۞۞ ۞۞ 7/9 
Oguz 2004 [42] ۞۞۞ ۞۞ ۞ 6/9 
Ou-Yang 2010 [43] ۞۞۞ ۞۞ ۞۞ 7/9 
Pedersen 2012 [44] ۞۞۞   ۞۞ 5/9 
Rosenberg 1987 [45] ۞۞   ۞ 3/9 
Thomaz 2013 [13] ۞۞۞۞   ۞۞ 6/9 
Wilberg 2016 [46] ۞۞۞۞ ۞۞ ۞۞۞ 9/9 
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Table 3 
Results of performed meta-analyses. 
Outcome 
Studies 
(Patients) 
Effect 95% CI P I2 (95% CI) tau2 (95% CI) 
95% 
prediction 
Tooth agenesis 5 (735) RR=2.47 1.30 to 4.71 0.006 61% (0% to 96%) 0.31 (0 to 5.03) 0.32 to 19.40 
Enamel hypoplasia 2 (242) RR=3.08 1.13 to 8.37 0.028 0% (0% to NC) 0 (0 to NC) NC 
Microdontia 4 (685) RR=12.41 3.05 to 50.60 <0.001 11% (0% to 94%) 0.23 (0 to 28.81) 0.31 to 505.09 
Arrested root development 2 (264) RR=2.75 1.84 to 4.10 <0.001 0% (0% to 100%) 0 (0 to 31.72) NC 
Premature apexification 3 (314) RR=4.53 1.01 to 20.35 0.049 0% (0% to NC) 0 (0 to NC) 0 to over 1000 
Unerupted teeth 2 (122) RR=1.43 0.40 to 5.15 0.583 69% (0% to 100%) 0.59 (0 to 873.45) NC 
Tooth discoloration 2 (122) RR=3.25 1.89 to 5.61 <0.001 0% (0% to 99%) 0 (0 to 20.16) NC 
Plaque index 3 (444) MD=0.60 0.32 to 0.89 <0.001 72% (1% to 99%) 0.05 (0 to 2.45) -2.68 to 3.89 
Gingival index 3 (444) MD=0.38 0.16 to 0.61 0.001 57% (0% to 99%) 0.02 (0 to 1.66) -2.00 to 2.77 
DMFT$ 3 (450) MD=3.07 2.26 to 3.88 <0.001 0% (0% to 96%) 0 (0 to 13.55) -2.17 to 8.32 
DT 2 (258) MD=3.55 2.71 to 4.39 <0.001 0% (0% to 100%) 0 (0 to 293.70) NC 
MT 2 (258) MD=-0.56 -1.06 to -0.07 0.025 0% (0% to 99%) 0 (0 to 18.18) NC 
High salivary buffer capacity* 2 (170) RR=1.03 0.26 to 4.07 0.969 93% (65% to NC) 0.92 (0.13 to NC) NC 
Salivary flow rate 2 (270) MD=-0.19 -0.24 to -0.13 <0.001 0% (0% to 100%) 0 (0 to 5.08) NC 
High S. mutans counts* 2 (284) RR=0.95 0.19 to 4.85 0.955 95% (75% to NC) 1.31 (0.21 to NC) NC 
CI: confidence interval; DMFT: decayed missing filled teeth; DT: decayed teeth; MD: mean difference; MT: missing teeth; NC: non-
calculable; RR: relative risk. 
* The 2 studies included in the meta-analysis are extremely heterogeneous (I2>75%) and no single study can be robustly omitted; The 
results of the meta-analyses cannot be relied upon and current evidence indicates statistical noise in the absence of an existing effect. 
$ A single study [35] was omitted from the initial meta-analysis to alleviate extreme heterogeneity (initial meta-analysis: 4 studies; 
MD=2.25; 95% CI=0.65 to 3.86; P=0.006; I2=83%) 
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Table 4 
Numbers needed to treat for statistically significant meta-analyses of binary outcomes. 
Outcome NNT 95% CI 
Tooth agenesis 7 3 to 30 
Enamel hypoplasia 8 3 to 119 
Microdontia 18 4 to 98 
Arrested root development 4 2 to 7 
Premature apexification 24 5 to 8334 
Tooth discoloration 2 1 to 6 
CI: confidence interval; NNT: number needed to treat. 
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Table 5a 
Summary of Findings Table according to the GRADE approach (binary outcomes). 
  Anticipated absolute effectsa (95% CI)   
Outcome 
Studies (patients) 
Relative effects 
(95% CI) 
CTR CH Difference 
Quality of the  
evidence (GRADE)c  
What happens 
Tooth agenesis 
5 studies (735 patients) 
RR 2.47 
(1.30 to 4.71) 
11.1%b 
27.4% 
(14.4 to 52.3%) 
16.3% more patients 
(3.3 to 41.2 more) 
 very lowc,d 
due to bias
May increase the risk of tooth 
agenesis 
Enamel hypoplasia 
2 studies (242 patients) 
RR 3.08 
(1.13 to 8.37) 
6.5%b 
20.0% 
(7.3 to 54.4%) 
13.5% more patients 
(0.8 to 47.9 more) 
 very lowc,d 
due to bias
May increase the risk of enamel 
hypoplasia 
Microdontia 
4 studies (685 patients) 
RR 12.41 
(3.05 to 50.60) 
0.5%b 
6.2% 
(1.5 to 25.3%) 
5.7% more patients 
(1.0 to 24.8 more) 
 very lowc,d 
due to bias
May increase the risk of 
microdontia 
Arrested root development 
2 studies (264 patients) 
RR 2.75 
(1.84 to 4.10) 
18.6%b 
51.2% 
(34.2 to 76.3%) 
32.6% more patients 
(15.6 to 57.7 more) 
 very lowc,d 
due to bias
May increase the risk of root 
development arrest 
Premature apexification 
3 studies (314 patients) 
RR 4.53 
(1.01 to 20.35) 
1.2%b 
5.4% 
(1.2 to 24.4%) 
4.2% more patients 
(0 to 23.2 more) 
 very lowc,d 
due to bias
May increase the risk of 
premature apexification 
Unerupted teeth 
2 studies (122 patients) 
RR 1.43 
(0.40 to 5.15) 
22.2%b 
31.7% 
(8.9 to 100%) 
9.5% more patients 
(13.3 less to 92.1 more) 
 very lowc,d 
due to bias
No difference on tooth eruption 
Tooth discoloration 
2 studies (122 patients) 
RR 3.25 
(1.89 to 5.61) 
22.2%b 
72.2% 
(42 to 100%) 
50.0% more patients 
(19.8 to 100.0 more) 
 very lowc,d 
due to bias
May increase the risk of tooth 
discoloration 
High salivary buffer 
capacity 
2 studies (270 patients) 
RR 1.03 
(0.26 to 4.07) 
44.3%b 
45.6% 
(11.5 to 100%) 
1.3% more patients 
(32.8 less to 100 more) 
 very lowc,d 
due to bias
No difference on salivary buffer 
capacity 
High S. mutans counts 
2 studies (284 patients) 
RR 0.95 
(0.19 to 4.85) 
38.9%b 
37.0% 
(7.4 to 100%) 
1.9% less patients 
(31.5 less to 100.0 more) 
 very lowc,d 
due to bias
No difference on high S. mutans 
counts 
Dental effects of chemotherapy administered to children (binary outcomes). 
Population & intervention: children receiving chemotherapy for any type of cancer. 
Settings: university clinics (Denmark, Hungary, Taiwan, Turkey). 
a The basis for the risk in the control group (e.g., the median control group risk across studies) is provided in footnotes. The risk in the intervention group (and its 95% 
confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 
b Reponse in the control group is based on random-effects meta-analytic pooling of the event rate from untreated patients of included studies. 
c Starts from "low", due to the inclusion of non-randomized studies. 
d Downgraded further by one point due to serious limitations (high risk of bias). 
 
CH: chemo-therapy; CI: confidence interval; CTR: control group (no chemotherapy); GRADE: Grading of Recommendations Assessment, Development and Evaluation. 
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Table 5b 
Summary of Findings Table according to the GRADE approach (continuous outcomes). 
  Anticipated absolute effectsa (95% CI)   
Outcome 
Studies (patients) 
Relative effects 
(95% CI) 
CTR CH Difference 
Quality of the  
evidence (GRADE)c  
What happens 
Plaque index 
3 studies (444 patients) 
- 0.82 - 
0.60 higher score 
(0.32 to 0.89 higher) 
 very lowc,d 
due to bias
May increase the plaque index of 
patients 
Gingival index 
3 studies (444 patients) 
- 0.72 - 
0.38 higher score 
(0.16 to 0.61 higher) 
 very lowc,d 
due to bias
May increase the gingival index 
of patients 
DMFT index 
3 studies (450 patients) 
- 3.84 - 
3.07 higher score 
(2.26 to 3.88 higher) 
 very lowc,d 
due to bias
May increase the DMFT index of 
patients 
DT index 
2 studies (258 patients) 
- 1.18 - 
3.55 higher score 
(2.71 to 4.39 higher) 
 very lowc,d 
due to bias
May increase the DT index of 
patients 
MT index 
2 studies (258 patients) 
- 2.25 - 
0.56 lower score 
(0.07 to 1.06 lower) 
 very lowc,d 
due to bias
May decrease the MT index of 
patients 
Salivary flow rate 
2 studies (270 patients) 
- 1.27 - 
0.19 less ml/min 
(0.13 to 0.24 less) 
 very lowc,d 
due to bias
May decrease the salivary flow 
rate of patients 
Dental effects of chemotherapy administered to children (continuous outcomes). 
Population & intervention: children receiving chemotherapy for any type of cancer. 
Settings: university clinics (Egypt, Hungary, Poland, Turkey). 
a The basis for the risk in the control group (e.g., the median control group risk across studies) is provided in footnotes. The risk in the intervention group (and its 95% 
confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 
b Reponse in the control group is based on random-effects meta-analytic pooling of the event rate from untreated patients of included studies. 
c Starts from "low", due to the inclusion of non-randomized studies. 
d Downgraded further by one point due to serious limitations (high risk of bias). 
 
CH, chemo-therapy; CI, confidence interval; CTR, control group (no chemotherapy); DMFT, decayed missing filled index; GRADE, Grading of Recommendations 
Assessment, Development and Evaluation. 
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Highlights 
 Indications of dental adverse effects from chemotherapy for childhood cancer exist. 
 This systematic review summarizes dental and oral adverse effects of chemotherapy. 
 Chemotherapy is associated with increased risk of dental anomalies like agenesis. 
 Chemotherapy is also associated with decreased salivary flow and increased caries. 
 Comprehensive hospital dental care might be needed for childhood cancer survivors. 
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APPENDIX 
 
Appendix 1. List of databases searched with search strategies, limitations, and hits (all searched on March 7, 2017). 
 
Database Pilot search Filter Hits 
MEDLINE (via PubMed) 
https://www.ncbi.nlm.nih.gov/pubmed 
chemotherapy AND (cancer OR oncol* OR survivor*) AND (child* OR pediatr* OR pedodon*) AND (tooth 
OR teeth OR dentition OR molar* OR incisor* OR canine* OR cuspid*) 
Humans 318 
Cochrane Database of Systematic Reviews 
http://www.cochranelibrary.com/ 
Same as PubMed   1 
Cochrane Central Register of Controlled Trials 
 http://www.cochranelibrary.com/ 
Same as PubMed   4 
Cochrane Database of Abstracts of Reviews of Effects 
 http://www.cochranelibrary.com/ 
Same as PubMed   0 
Virtual Health Library* 
http://bvsalud.org/en/ 
Same as PubMed   12 
Scopus 
https://www.scopus.com/ 
Same as PubMed Human/Humans 264 
Web of Science 
 https://apps.webofknowledge.com/ 
Same as PubMed   113 
ClinicalTrials.gov https://clinicaltrials.gov/ 
chemotherapy AND (cancer OR oncology OR survivor) AND (child OR children OR childhood OR pediatric 
OR pedodontic) AND (tooth OR teeth OR dentition OR molar OR incisor OR canine OR cuspid) 
  29 
SUM (with duplicates) 741 
SUM (without duplicates) 551 
* covering among other the databases LILACS (Literatura Latino Americana em Ciências da Saúde), BBO (Brazilian Bibliography of Dentistry), WHOLIS (WHO 
Library Database), IBECS (Índice Bibliográfico Español en Ciencias de la Salud), CUMED (Cuba Medicina), PAHO (Pan American Health Organization), and 
MedCarib (Caribbean Health Sciences Literature). 
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Appendix 2. List of studies identified by the literature searches and their exclusion/inclusion status with reasons. 
Nr. Paper Status 
1 
[No authors] Clinical guideline on dental management of pediatric patients receiving chemotherapy, hematopoietic cell 
transplantation, and/or radiation. Pediatric dentistry. 2004;26(7 Suppl):144-9. 
Excluded by title 
2 {NCT00002641} Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma. [Completed] Excluded by title 
3 
{NCT00002701} Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute 
Promyelocytic Leukemia. [Unknown status] 
Excluded by title 
4 
{NCT00002764} Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft 
Tissue Sarcoma. [Completed] 
Excluded by title 
5 
{NCT00002840} Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic 
Oligodendroglioma. [Completed] 
Excluded by title 
6 
{NCT00002895} Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating 
Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer. [Completed] 
Excluded by title 
7 
{NCT00003636} Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or 
Fallopian Tube Cancer. [Completed] 
Excluded by title 
8 {NCT00003643} Combination Chemotherapy in Treating Men With Germ Cell Cancer. [Unknown status]. Excluded by title 
9 
{NCT00005584} Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's 
Lymphoma. [Active, not recruiting] 
Excluded by title 
10 {NCT00014300} Glufosfamide in Treating Patients With Recurrent Glioblastoma Multiforme. [Completed] Excluded by title 
11 
{NCT00017095} Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and 
Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer. [Completed] 
Excluded by title 
12 {NCT00023842} BCG With or Without Mitomycin in Treating Patients With Bladder Cancer. [Completed] Excluded by title 
13 {NCT00041249} Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma. [Completed] Excluded by title 
14 {NCT00042887} Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer. [Terminated] Excluded by title 
15 
{NCT00053807} Interleukin-2, Interferon Alfa, and Fluorouracil Compared With Observation in Treating Patients Who Have 
Undergone Surgery for Kidney Cancer. [Completed] 
Excluded by title 
16 
{NCT00085163} Celecoxib Combined With Fluorouracil and Leucovorin in Treating Patients With Resected Stage III 
Adenocarcinoma (Cancer) of the Colon. [Completed] 
Excluded by title 
17 
{NCT00085735} Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young 
Patients With Newly Diagnosed Standard-Risk Medulloblastoma. [Completed] 
Excluded by title 
18 
{NCT00096187} Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Low-Risk Gestational 
Trophoblastic Tumor After a Molar Pregnancy. [Terminated] 
Excluded by title 
19 
{NCT00227630} Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With 
Malignant Pleural Mesothelioma. [Completed] 
Excluded by title 
20 
{NCT00392327} Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously 
Untreated, High-Risk Medulloblastoma. [Recruiting] 
Excluded by title 
21 
{NCT01553071} Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies. 
[Recruiting] 
Excluded by title 
22 
{NCT01898117} Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Bevacizumab as First-line 
Treatment in Advanced Triple Negative Breast Cancer. [Recruiting] 
Excluded by title 
23 
{NCT02276053} Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors. 
[Recruiting] 
Excluded by title 
24 
{NCT02772094} Dendritic Cell-Based Tumor Vaccine Adjuvant Immunotherapy of Human Glioblastoma Multiforme (WHO 
Grade IV Gliomas). [Active, not recruiting] 
Excluded by title 
25 {NCT02892877} The French National Reference Centre of GTD. [Recruiting] Excluded by title 
26 
Abdolkarimi B, Zareifar S, Mokhtari M. Face bones involvement and relapse in a case of childhood acute leukemia. Iranian 
Journal of Blood and Cancer. 2015;7(2):105-9. 
Excluded by title 
27 
Ajibola A. Novel insights into the health importance of natural honey. Malaysian Journal of Medical Sciences. 2015;22(5):7-
22. 
Excluded by title 
28 
Alberth M, Torok J, Nemes J, Kiss C, Marton I. [Structural disorder of dental enamel caused by antineoplastic agents--case 
report]. Fogorvosi szemle. 2002;95(5):189-93. 
Excluded by title 
29 
Amezcua CA, Bahador A, Naidu YM, Felix JC. Expression of human telomerase reverse transcriptase, the catalytic subunit 
of telomerase, is associated with the development of persistent disease in complete hydatidiform moles. American journal 
of obstetrics and gynecology. 2001;184(7):1441-6. 
Excluded by title 
30 
Annibali S, Cristalli MP, Solidani M, Ciavarella D, La Monaca G, Suriano MM, et al. Langerhans cell histiocytosis: 
Oral/periodontal involvement in adult patients. Oral Diseases. 2009;15(8):596-601. 
Excluded by title 
31 
Atas E, Kesik V. The False Positivity of Positron Emission Tomography Owing to Teething. Indian pediatrics. 
2015;52(5):441. 
Excluded by title 
32 
Barberia E, Hernandez C, Miralles V, Maroto M. Paediatric patients receiving oncology therapy: review of the literature and 
oral management guidelines. European journal of paediatric dentistry : official journal of European Academy of Paediatric 
Dentistry. 2008;9(4):188-94. 
Excluded by title 
33 
Bardellini E, Amadori F, Majorana A. Oral hygiene grade and quality of life in children with chemotherapy-related oral 
mucositis: a randomized study on the impact of a fluoride toothpaste with salivary enzymes, essential oils, proteins and 
colostrum extract versus a fluoride toothpaste without menthol. International Journal of Dental Hygiene. 2016;14(4):314-9. 
Excluded by title 
34 
Bascones-Martinez A, Munoz-Corcuera M, Gomez-Font R. [Oral secondary effects of radiotherapy and chemotherapy in 
cancer of the cervicofacial region]. Medicina clinica. 2013;141(2):77-81. 
Excluded by title 
35 
Batschinski K, Dervisis NG, Kitchell BE. Evaluation of ifosfamide salvage therapy formetastatic canine osteosarcoma. 
Veterinary and Comparative Oncology. 2014;12(4):249-57. 
Excluded by title 
36 
Benson RE, Rodd HD, North S, Loescher AR, Farthing PM, Payne M. Leukaemic infiltration of the mandible in a young girl. 
International journal of paediatric dentistry. 2007;17(2):145-50. 
Excluded by title 
37 
Berkowitz RJ, Neuman P, Spalding P, Novak L, Strandjord S, Coccia PF. Developmental orofacial deficits associated with 
multimodal cancer therapy: case report. Pediatric dentistry. 1989;11(3):227-31. 
Excluded by title 
38 
Beyazit Y, Kart T, Kuscu A, Arslan A, Kurt M, Aktas B, et al. Successful management of bleeding after dental procedures 
with application of blood stopper: a single center prospective trial. The journal of contemporary dental practice. 
Excluded by title 
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2011;12(5):379-84. 
39 
Birkebaek NH, Helgestad JE. [Late endocrine and growth sequelae after cancer treatment in children]. Ugeskrift for laeger. 
1994;156(32):4559-61, 64-5. 
Excluded by title 
40 
Bisogno G, Soloni P, Conte M, Podda M, Ferrari A, Garaventa A, et al. Esthesioneuroblastoma in pediatric and adolescent 
age. A report from the TREP project in cooperation with the Italian Neuroblastoma and Soft Tissue Sarcoma Committees. 
BMC cancer. 2012;12. 
Excluded by title 
41 
Bolze PA, Attia J, Massardier J, Seckl MJ, Massuger L, van Trommel N, et al. Formalised consensus of the European 
Organisation for Treatment of Trophoblastic Diseases on management of gestational trophoblastic diseases. European 
journal of cancer (Oxford, England : 1990). 2015;51(13):1725-31. 
Excluded by title 
42 
Bonazzi C, Urso M, Dell'Anna T, Sacco S, Buda A, Cantu MG. Placental site trophoblastic tumor - An overview. Journal of 
Reproductive Medicine. 2004;49(8):585-8. 
Excluded by title 
43 
Bonazzi C, Urso M, Dell'Anna T, Sacco S, Buda A, Cantu MG. Placental site trophoblastic tumor: an overview. The Journal 
of reproductive medicine. 2004;49(8):585-8. 
Excluded by title 
44 
Brazao-Silva MT, Fernandes AV, Faria PR, Cardoso SV, Loyola AM. Ewing's sarcoma of the mandible in a young child. 
Brazilian dental journal. 2010;21(1):74-9. 
Excluded by title 
45 
Brazão-Silva MT, Loyola AM, Cardoso SV, Fernandes AV, Faria PRd. Ewing&#039;s sarcoma of the mandible in a young 
child. Brazilian dental journal. 2010;21(1):74-9. 
Excluded by title 
46 Briefs L, Selbst SM. Pediatric emergency medicine. Pediatric Emergency Care. 2015;31(5):373-5. Excluded by title 
47 Brook I. Fusobacterial infections in children. Current Infectious Disease Reports. 2013;15(3):288-94. Excluded by title 
48 
Burtner CR, Beard BC, Kennedy DR, Wohlfahrt ME, Adair JE, Trobridge GD, et al. Intravenous injection of a foamy virus 
vector to correct canine SCID-X1. Blood. 2014;123(23):3578-84. 
Excluded by title 
49 
Butler J, Hooper KA, Petrie S, Lee R, Maurer-Stroh S, Reh L, et al. Estimating the fitness advantage conferred by 
permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses. PLoS pathogens. 
2014;10(4):e1004065. 
Excluded by title 
50 
Cabrerizo Merino MC, Onate Sanchez RE, Garcia Ballesta C, Ruiz Jimenez JI, De las Heras Gonzalez M. Dental 
anomalies caused by oncological treatment: case report. The Journal of clinical pediatric dentistry. 1998;22(3):261-4. 
Excluded by title 
51 
Campana D, Coustan-Smith E, Manabe A, Kumagai M, Murti KG, Silvennoinen O, et al. Human B-cell progenitors and 
bone marrow microenvironment. Human cell. 1996;9(4):317-22. 
Excluded by title 
52 
Captier G, Montoya P, Duche R, Le Barazer M, Bigorre M, Margueritte G. [Synovial sarcoma of the mandible in children. 
Apropos of a case]. Revue de stomatologie et de chirurgie maxillo-faciale. 1999;100(4):187-91. 
Excluded by title 
53 
Carlsson G, Wahlin YB, Johansson A, Olsson A, Eriksson T, Claesson R, et al. Periodontal disease in patients from the 
original Kostmann family with severe congenital neutropenia. Journal of periodontology. 2006;77(4):744-51. 
Excluded by title 
54 
Carol H, Fan MM, Harasym TO, Boehm I, Mayer LD, Houghton P, et al. Efficacy of CPX-351, (cytarabine:daunorubicin) 
liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing 
Program. Pediatric blood & cancer. 2015;62(1):65-71. 
Excluded by title 
55 
Cetiner S, Alpaslan C. Long-term effects of cancer therapy on dental development: a case report. The Journal of clinical 
pediatric dentistry. 2004;28(4):351-3. 
Excluded by title 
56 
Chen Y, Zheng XL, Fang DL, Yang Y, Zhang JK, Li HL, et al. Dual agent loaded PLGA nanoparticles enhanced antitumor 
activity in a multidrug-resistant breast tumor eenograft model. International journal of molecular sciences. 2014;15(2):2761-
72. 
Excluded by title 
57 
Cheng CF, Huang WH, Tsai TP, Ko EW, Liao YF. Effects of cancer therapy on dental and maxillofacial development in 
children: report of case. ASDC journal of dentistry for children. 2000;67(3):218-22, 161. 
Excluded by title 
58 
Childs SK, Kozak KR, Friedmann AM, Yeap BY, Adams J, MacDonald SM, et al. Proton radiotherapy for parameningeal 
rhabdomyosarcoma: clinical outcomes and late effects. International journal of radiation oncology, biology, physics. 
2012;82(2):635-42. 
Excluded by title 
59 
Cil T, Altintas A, Tamam Y, Battaloglu E, Isikdogan A. Low dose vincristine-induced severe polyneuropathy in a Hodgkin 
lymphoma patient: a case report (vincristine-induced severe polyneuropathy). Journal of pediatric hematology/oncology. 
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60 
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children: A three- period crossover study comparing morphine and hydromorphone. J Pediatr 1996;129(5):722-8. 
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61 
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Appendix 3. Assessment of the methodological adequacy (potentially associated with risk of bias) of included studies with a modified Newcastle-Ottawa tool for cohort studies. 
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Selection 
               Is the case definition adequate? ۞ ۞ ۞ ۞ ۞ ۞ ۞ ۞ ۞ ۞ ۞ ۞ ۞ ۞ ۞ 
Representativeness of the cases ۞ ۞ ۞ ۞ 
 
۞ ۞ 
  
۞ 
 
۞ ۞ ۞ ۞ 
Selection of Controls 
  
NA ۞ 
 
NA ۞ 
 
۞ 
 
۞ 
 
NA ۞ ۞ 
Definition of Controls ۞ ۞ NA ۞ ۞ NA 
 
۞ ۞ ۞ ۞ ۞ NA ۞ ۞ 
Comparability 
               Comparability of cases and controls on 
the basis of the design or analysis 
۞۞ ۞۞ NA ۞۞ ۞ NA ۞ ۞ ۞۞ ۞۞ ۞۞ 
 
NA 
 
۞۞ 
Exposure 
               
Ascertainment of exposure ۞ ۞ ۞ ۞ ۞ ۞ ۞ ۞ ۞ ۞ ۞ ۞ ۞ ۞ ۞ 
Same method of ascertainment for cases 
and controls*   
NA 
 
 NA 
 
 ۞  ۞ ۞ NA ۞ ۞ 
Non-Response Rate 
  
NA 
 
 NA 
 
 
 
 
  
NA 
 
۞ 
NA: not applicable 
* Star was given only when a study explicitly stated that the patient in the control group were unexposed. 
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Appendix 4. Re-analysis with univariable/multivariable linear regression of DMFT data from the Cubukcu et al., 2008 study. 
  Univariable  Multivariable 
Factor Category Coefficient 95% CI P  Coefficient 95% CI P 
Chemotherapy Yes 0.02 -1.16,1.21 0.97  0.01 -1.14,1.16 0.99 
 No Reference    Reference   
         
Gender Male -0.69 -1.92,0.53 0.26  Not added - - 
 Female Reference    Reference   
         
Age at diagnosis group 6 years or older 1.49 0.25,2.73 0.02  1.49 0.23,2.74 0.02 
 Up to 5 years Reference    Reference   
CI: confidence interval. 
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Appendix 5. Random-effects meta-regression analyses of tooth agenesis with modifying factors. 
Outcome Studies RR 95% CI P 
Patient age (per year) 3 0.54 0.01 to 45.09 0.33 
Patient sex (per % male patients in the sample)  4 0.99 0.85 to 1.17 0.90 
Follow-up (per year) 4 1.30 0.50 to 3.39 0.36 
CI: confidence interval; RR, relative risk. 
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Appendix 6. Sensitivity analyses between large and non-large studies (judged arbitrarily with a cut-off of 100 patients/study). 
 Large  Non-large  
Outcome Studies Effect 95% CI  Studies Effect 95% CI P (large vs non-large) 
Tooth agenesis 2 RR=1.58 0.95 to 2.63   3 RR=3.71 1.38 to 9.94 0.39 
Enamel hypoplasia 1 RR=3.00 0.32 to 28.62   1 RR=3.10 1.01 to 9.46 NC 
Microdontia 2 RR=16.74 1.18 to 236.64  2 RR=10.19 1.24 to 83.92 0.88 
Arrested root development 1 RR=2.94 1.84 to 4.71  1 RR=2.29 1.07 to 4.93 NC 
Premature apexification 1 RR=5.00 0.59 to 42.37  2 RR=4.11 0.50 to 34.03 0.61 
Unerupted teeth 0 - -  2 RR=1.43 0.40 to 5.15 - 
Tooth discoloration 0 - -  2 RR=3.25 1.89 to 5.61 - 
Plaque index 2 MD=0.61 0.12 to 1.10  1 MD=0.59 0.32 to 0.86 0.93 
Gingival index 2 MD=0.46 0.16 to 0.76   1 MD=0.24 -0.01 to 0.49 0.60 
DMFT 2 MD=3.45 2.44 to 4.46  1 MD=2.40 1.05 to 3.75 0.13 
DT 1 MD=3.89 2.75 to 5.03  1 MD=3.13 1.88 to 4.38 NC 
MT 1 MD=-0.41 -1.53 to 0.71  1 MD=-0.60 -1.15 to -0.05 NC 
High salivary buffer capacity 0 - -   RR=1.03 0.26 to 4.07 - 
Salivary flow rate 1 MD=-0.18 -0.24 to -0.12  1 MD=-0.28 -0.50 to -0.06 NC 
High S. mutans counts 1 RR=2.18 1.34 to 3.56  1 RR=0.41 0.24 to 0.70 NC 
CI: confidence interval; DMFT: decayed missing filled teeth; DT: decayed teeth; MD: mean difference; MT: missing teeth; NC: non-
calculable; RR: relative risk. 
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Appendix 7. Additional review details 
 
Contributors 
DMB, SNP and TE conceived the study. DMB wrote the first draft of the protocol and all authors revised 
the protocol. DMB and SNP did study selection, data extraction, and methodological assessment, while 
GR and TE resolved conflicts. SNP performed the analysis and DMB wrote the first draft of the 
manuscript. All authors contributed to critical revision of the manuscript for important intellectual content 
and approved the final version. SNP is the guarantor. 
 
Deviations from the initial protocol 
 The primary outcome of the review was changed from caries experience to tooth agenesis. This was 
done as caries experience might correspond to cavitated/non-cavitated lesions of variable size that 
might be treated with a simple filling—whereas tooth agenesis results in obvious tooth loss and 
therefore greater burden and treatment costs. Tooth agenesis was already included in the initial 
protocol, but as a secondary outcome. 
 We also decided to adjust the list of secondary outcomes to all outcomes that were identified and 
included in meta-analyses. These are however listed as secondary outcomes in the paper and are 
given lower priority. 
 Additional subgroup/meta-regression analyses were planned in the review protocol, but could not be 
conducted as only one meta-analysis included more than 5 studies and limited data was available. 
 Sensitivity analyses planned a priori between randomized and non-randomized studies could not be 
conducted as no randomized trials existed. Likewise, sensitivity analysis on methodological grounds 
between prospective and retrospective non-randomized studies could not be conducted, as only 
retrospective studies were identified. 
 Indications of reporting biases (including small-study effects and publication bias) were planned to be 
conducted for meta-analyses of ≥ 10 studies (Sterne et al., 2011) using contour-enhanced funnel plots 
and Egger’s test (Egger et al., 1997). However, all meta-analyses included less than 10 studies and 
such analyses were not possible. 
 
